author-photo

Robert Kleinfield

3

Papers

23

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Recommended phase (Ph) II dose (RP2D) selection for investigational Aurora A kinase (AAK) inhibitor MLN8237 (Alisertib; A) combined with paclitaxel (P): Clinical pharmacokinetics (PK), drug-drug interaction (DDI) assessment, and translational exposure-efficacy modeling.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure–safety relationships

2015 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (22)